{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-006504","form_type":"8-K","ticker":"RNXT","cik":"0001574094","company_name":"RenovoRx, Inc.","filed_at":"2023-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.659926+00:00","generated_at":"2026-06-18T15:09:32.270032+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"RenovoRx reports FY2022 net loss $9.9M; Phase III pancreatic cancer trial interim analysis triggered","bullets":["Net loss $9.9M for FY2022 vs $6.3M in 2021; diluted EPS ($1.09) vs ($1.21).","Cash $6.4M as of Dec 31, 2022; expects to fund operations into Q3 2023.","Phase III TIGeR-PaC trial: first interim analysis triggered after 26 events (30% of 86); DMC review underway; results expected within a week.","47 of 114 target patients randomized; second interim analysis expected in 2024.","Operating expenses $10.0M, up from $5.7M; R&D $4.3M, G&A $5.6M."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-006504","json":"https://secwatch.observer/filing/0001493152-23-006504.json","markdown":"https://secwatch.observer/filing/0001493152-23-006504.md","text":"https://secwatch.observer/filing/0001493152-23-006504.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574094/000149315223006504/0001493152-23-006504-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574094/000149315223006504/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T15:09:32.270032+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"df2bece91417e0e259b32e6195104ce303403d52","claim":"RenovoRx, Inc. reported year ended December 31, 2022 results: net income Net loss was $9.9 million for the ended December 31, 2022, EPS Net loss per share, basic and diluted were ($1.09) for the year ended December 31, 2022.","evidence_excerpt":"● Net loss was $9.9 million for the ended December 31, 2022, compared to net loss of $6.3 million for year ended December 31, 2021. ● Net loss per share, basic and diluted were ($1.09) for the year ended December 31, 2022, compared to ($1.21) for the year ended December 31, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1574094/000149315223006504/0001493152-23-006504-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2022"},{"label":"Net income","value":"Net loss was $9.9 million for the ended December 31, 2022"},{"label":"EPS","value":"Net loss per share, basic and diluted were ($1.09) for the year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}